Fubotv Inc vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 5.9× Fubotv Inc's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| FUBO | IOVA | |
|---|---|---|
Market Cap | $1.02B | $6.04B |
Volume | 978,631 | 14,805,993 |
Sector | Media | Health |
52-Week High | $48.96 | $14.82 |
52-Week Low | $8.09 | $1.81 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.19B | $5.97B |
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.35, up 1.08% with bearish technical signals but attractive valuation metrics including P/E of 2.43 and P/S of 0.19. The company shows improving financials with revenue growth to $1.62B in 2024 and projected profitability in 2025. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a turnaround opportunity with deep valuation discounts and projected EBITDA growth, though execution risks remain high. The stock offers significant upside to analyst consensus target of $63.38 but faces challenges from persistent cash burn and competitive streaming landscape. Investors should weigh the potential for operational improvements against ongoing financial volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →